A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin.
- Author:
Zhi-Gang CAO
1
;
Hong-Wei ZHOU
;
Chao-Jin PENG
;
Mo LIU
;
Yu DU
;
Qing-Ming YANG
Author Information
- Publication Type:Case Reports
- MeSH: Adolescent; Antineoplastic Agents; therapeutic use; Female; Hodgkin Disease; diagnostic imaging; drug therapy; metabolism; pathology; therapy; Humans; Immunoconjugates; therapeutic use; Ki-1 Antigen; metabolism; Neoplasm Recurrence, Local; PAX5 Transcription Factor; metabolism; Positron-Emission Tomography; Stem Cell Transplantation; Tomography, X-Ray Computed
- From:Chinese Journal of Cancer 2013;32(9):520-523
- CountryChina
- Language:English
- Abstract: At present, approximately 20% of Hodgkin lymphomas (HL) are relapsed and refractory, and therapeutic methods including chemotherapy, radiotherapy, and even stem cell transplantation are unsatisfactory. Brentuximab vedotin, composed of CD30 antibody and a chemotherapeutic agent, is a new targeted drug that eradicates tumor cells by binding to the CD30 antigen on their surface. In clinical trials, the response rate and complete remission rate of this drug were 73% and 40%, respectively, for relapsed and refractory HL. Here we report a case of CD30-positive relapsed and refractory HL that was treated with brentuximab. Before the treatment with brentuximab, the patient underwent chemotherapy, radiotherapy, and autologous stem cell transplantation. However, the disease continued to progress, affecting multiple organs and prompting symptoms such as persistent fever. After the treatment with brentuximab, the patient's condition improved. Body temperature returned to normal after 4 days. Lung nodules were reduced in size and number after a single course of treatment, and PET/CT showed partial remission and complete remission after 3 and 6 courses of treatment, respectively. The entire treatment process progressed smoothly, though the patient experienced some symptoms due to chemotherapy, including peripheral neuritis of the limbs, irritating dry cough, and mild increase in aminotransferase. No serious adverse effects were observed. The current general condition of the patient is good; the continuous complete remission has amounted to 6 months.
